Reports of metastatic hepatocellular carcinoma (HCC) without a primary liver tumor are rare. Here we present a case of isolated HCC that had metastasized to the pelvic bone without a primary focus. A 73-year-old man presented with severe back and right-leg pain. Radiological examinations, including computed tomography (CT) and magnetic resonance imaging (MRI), revealed a huge mass on the pelvic bone (13×10 cm). He underwent an incisional biopsy, and the results of the subsequent histological examination were consistent with metastatic hepatocellular carcinoma. The tumor cells were positive for cytokeratin (AE1/AE3), hepatocyte paraffin 1, and glypican-3, and negative for CD56, chromogranin A, and synaptophysin on immunohistochemical staining. Examination of the liver by CT, MRI, positron-emission tomography scan, and angiography produced no evidence of a primary tumor. Radiotherapy and transarterial chemoembolization were performed on the pelvic bone, followed by systemic chemotherapy. These combination treatments resulted in tumor regression with necrotic changes. However, multiple lung metastases developed 1 year after the treatment, and the patient was treated with additional systemic chemotherapy. (Korean J Hepatol 2012;18:89-93)
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common cancers and its incidence is increasing worldwide. 1 As the treatment of HCC has remarkably improved, the survival of patients with HCC has been prolonged.
Consequently, extrahepatic metastasis of HCC is now diagnosed more frequently and the incidence of bone metastasis from HCC is also increasing. 2, 3 However, cases of extrahepatic HCC without a detectable primary liver tumor have rarely been reported; in fact, bone metastasis from HCC, single or multiple, without the presence of a primary tumor has been reported in only six cases worldwide. [4] [5] [6] [7] [8] [9] Because of insufficient experience with these cases, diagnostic and treatment approaches for these patients are challenging. Here, we present a case of metastatic HCC arising from the pelvic bone without a primary focus.
CASE REPORT
A 73-year-old man was admitted to our hospital for evaluation of severe back pain and right leg pain for 1 month. The medical history of patient revealed that he was diagnosed as a hepatitis B virus (HBV) carrier about 20 years earlier, but was lost to follow up. The patient was not a heavy drinker or smoker. There was no significant family 
DISCUSSION
In this case, the final diagnosis was an isolated pelvic bone metastasis from HCC with unknown primary origin.
Extrahepatic metastases from unknown primary HCC are exceptionally rare and only a few case reports of bone metastasis have been documented. [4] [5] [6] [7] [8] [9] The hypothesis for explaining this unusual phenomenon is that the metastases are from a microhepatocellular carcinoma, which regressed spontaneously or was destroyed by the activated immune system. 6, 7, 10 However, the carcinogenesis mechanism as well as the natural history of this rare phenomenon is not well-known yet. 7 Thus, the diagnostic approach and treatment have been performed on an individual basis.
Although the nature of tumor cell could be confirmed by histological examination including immunohistochemical stains, we had to make a differential diagnosis with hepatoid adenocarcinoma and HCC development from ectopic liver. [11] [12] [13] Indeed, as there is no specific pathologic finding that could distinguish metastatic HCC from hepatoid adenocarcinoma or HCC arising from ectopic liver, information about involved organ, the presence of chronic liver disease and the degree of liver disease have been used as additional basis for differential diagnosis in previous studies. [4] [5] [6] [7] [8] [9] to increase the survival rate of HCC patients with bone metastasis, their ability to reduce pain and to increase quality of life has been reported in previous studies. 15, 20 In our case, back and leg pain were relieved after treatment.
Moreover, TACE was performed without complications to the pelvic bone metastasis in our case. Indeed, TACE was successfully performed for bone metastasis of HCC in previous studies, 6, 21 and these results suggest that TACE could be considered as a treatment option for a bone metastasis from HCC. Even though multiple lung metastases developed, the tumor was well controlled for 12 months after the treatment. In conclusion, we think that individualized and multimodality treatment would be beneficial in such cases.
In summary, we reported a rare case of metastatic HCC of the pelvic bone without a known primary origin. In such cases, tissue biopsy and radiological examination should be performed and diagnosis should be made based on both pathological examination and clinical features. Individualized and combined modality treatment could be considered in such cases.
